Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 20/20 | 0.54 |
| ▸ | ESR1 | P03372 | 12/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16581404 | 0.89 | ESR2 (0.55) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2951103 | 0.89 | ESR2 (0.61) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL16581407 | 0.84 | TRPA1 (0.49) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2951451 | 0.82 | ESR2 (0.60) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2043249 | 0.82 | TRPA1 (0.54) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL9074317 | 0.81 | ESR2 (0.57) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2045808 | 0.80 | ESR2 (0.52) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL13379632 | 0.78 | ESR2 (0.50) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL9074414 | 0.77 | ESR2 (0.53) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL16581482 | 0.77 | ESR2 (0.45) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958942-B1 | Trisoxetane compound, process for producing the same and optical waveguide using the same | NITTO DENKO CORP (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-7759503-B2 | Trisoxetane compound, process for producing the same, and optical waveguide using the same | NITTO DENKO CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20080221341-A1 | Trisoxetane compound, process for producing the same, and opitcal waveguide using the same | NITTO DENKO CORPORATION (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1958942-A1 | Trisoxetane compound, process for producing the same and optical waveguide using the same | NITTO DENKO CORPORATION (JP) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221341-A1 | Trisoxetane compound, process for producing the same, and opitcal waveguide using the same | OXER1, OPRD1, TRPC6 | ESR2 3733/4885ESR1 3532/4885CYP3A4 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.